Roche Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Roche said its experimental Alzheimer's drug failed to meet its main goals in a mid-stage study, a result likely to bolster the belief that drugs need to be given in earlier stages of the disease to slow patients' decline.

The Swiss drugmaker's treatment known as crenezumab was tested in patients with mild-to-moderate forms of Alzheimer's, a fatal, brain-wasting disease that gradually robs patients of their ability to think and care for themselves.

Help employers find you! Check out all the jobs and post your resume.

Back to news